Filing Flows › Vanda Pharmaceuticals (VNDA) › HETLIOZ® net product sales revenue
Vanda Pharmaceuticals (VNDA) HETLIOZ® net product sales revenue by quarter
Vanda Pharmaceuticals' HETLIOZ® net product sales revenue was $21.7M in Q3 2026 (third quarter 2026), +289% from Q2 2026. Over the last 7 quarters it ranged from $5.6M (Q2 2026) to $21.7M (Q3 2026).
| Quarter | HETLIOZ® net product sales revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $21.7M | +289% | +21% |
| Q2 2026 | $5.6M | -65% | -66% |
| Q1 2026 | $15.9M | -3% | -24% |
| Q4 2025 | $16.4M | -9% | — |
| Q3 2025 | $18.0M | +11% | — |
| Q2 2025 | $16.2M | -22% | — |
| Q1 2025 | $20.9M | — | — |
Q3 2026 at a glance
Vanda Pharmaceuticals, Q3 2026: revenue $69.8M (+24% year over year), operating margin -33.7%, net loss $22.6M, operating cash flow −$28.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Vanda Pharmaceuticals' HETLIOZ® net product sales revenue?
Vanda Pharmaceuticals' HETLIOZ® net product sales revenue was $21.7M in Q3 2026 (third quarter 2026), +289% from Q2 2026.
How has Vanda Pharmaceuticals' HETLIOZ® net product sales revenue changed?
Over the last 7 quarters it ranged from $5.6M (Q2 2026) to $21.7M (Q3 2026).